F. Rothweiler

Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform

This study develops a phenotypic screening platform using caspase 3/7 activity to identify antiviral compounds against SARS-CoV-2, including novel candidates and combinations.

Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells

This study identifies intrinsic and acquired resistance mechanisms to CNDAC and related nucleoside analogues in AML cells, showing distinct roles of SAMHD1 and DCK.

Drug-adapted cancer cell lines reveal drug-induced heterogeneity and enable the identification of biomarker candidates for the acquired resistance setting

The paper investigates drug-induced heterogeneity in cancer cell lines and identifies biomarkers for acquired resistance to YM155.

Testing of the survivin suppressant YM155 in a large panel of drug-resistant neuroblastoma cell lines

This study tests YM155 in 101 neuroblastoma cell lines, revealing ABCB1 and ABCC1 as mediators of resistance and highlighting cross-resistance differences between drug-adapted lines.

SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine

This study identifies SAMHD1 as a key regulator of nelarabine response in acute lymphoblastic leukaemias, showing lineage-specific differences in SAMHD1 expression and methylation.

The thrombopoietin receptor agonist eltrombopag inhibits human cytomegalovirus replication via iron chelation

This paper shows eltrombopag inhibits HCMV replication via iron chelation, effective against drug-resistant strains and synergistic with ganciclovir.

TP53 mutations and drug sensitivity in acute myeloid leukaemia cells with acquired MDM2 inhibitor resistance

This study establishes MDM2 inhibitor-resistant AML sub-lines and finds that resistance arises from pre-existing TP53 mutations or de novo mutations, with variable drug sensitivity despite loss of p53 function.